MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on September 12, 2005; DOI: 10.1124/mol.105.014407


0026-895X/05/6806-1623-1635$20.00
Mol Pharmacol 68:1623-1635, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.014407v1
68/6/1623    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Picone, R. P.
Right arrow Articles by Makriyannis, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Picone, R. P.
Right arrow Articles by Makriyannis, A.

(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor

Robert P. Picone, Atmaram D. Khanolkar, Wei Xu1, Lionel A. Ayotte, Ganesh A. Thakur1, Dow P. Hurst, Mary E. Abood, Patricia H. Reggio, Donna J. Fournier, and Alexandros Makriyannis1

Center for Drug Discovery (R.P.P., A.D.K., W.X., L.A.A., G.A.T., D.J.F., A.M.), Departments of Pharmaceutical Sciences (R.P.P., A.D.K., W.X., L.A.A., G.A.T., D.J.F., A.M.) and Molecular & Cell Biology (A.M.), University of Connecticut, Storrs, Connecticut; Department of Chemistry & Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina (D.P.H., P.H.R.); and Forbes Norris Amyotrophic Lateral Sclerosis/Muscular Dystrophy Association Research Center, California Pacific Medical Center, San Francisco, California (M.E.A.)

The CB1 cannabinoid receptor has been shown to play important physiological roles in the central nervous system, as well as peripherally, and is a target for development of therapeutic medications. To gain insight on the ligand binding site(s) and structural features of activation, we designed and synthesized (-)-7'-isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a classical cannabinoid affinity label that incorporates an isothiocyanate substituent as an electrophilic reactive group capable of interacting irreversibly with a suitably located and properly oriented nucleophilic amino acid residue at or near the binding site. To obtain evidence for the site of covalent attachment of AM841, C6.47, identified in part by interactive ligand docking, was mutated to serine, alanine, and leucine to reduce or eliminate the nucleophilic character. Wild-type (WT) and mutant CB1 receptors were evaluated for their abilities to recognize a series of cannabinergic ligands. Each bound comparably to WT, excluding C6.47L, which displayed a reduced affinity for 3H-labeled (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol (CP55940), AM841, 11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM4056), and (-)-7'-bromo-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM4043) and an improvement in affinity for (-)-trans-{Delta}9-tetrahydrocannabinol ({Delta}9-THC). The affinity of 3H-labeled [2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl](naphthyl)methanone (WIN55212-2) was unchanged across all mutants. It is noteworthy that AM841 was shown to bind irreversibly to WT CB1 but exhibited no covalent attachment with the mutants and behaved as an agonist suggesting irreversible attachment to C6.47 maintains CB1 in its active state. The evidence presented identifies C6.47 as the site of covalent bond formation with AM841 and combined with the binding data fully supports the molecular modeling. These studies present the first report of tandem applications of affinity labeling, site-directed mutagenesis, and interactive ligand docking for CB1.


Received April 28, 2005; accepted September 12, 2005

Address correspondence to: Alexandros Makriyannis, Center for Drug Discovery, Northeastern University, Boston, MA 02115. E-mail: a.makriyannis{at}neu.edu




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
A. Kapur, D. P. Hurst, D. Fleischer, R. Whitnell, G. A. Thakur, A. Makriyannis, P. H. Reggio, and M. E. Abood
Mutation Studies of Ser7.39 and Ser2.60 in the Human CB1 Cannabinoid Receptor: Evidence for a Serine-Induced Bend in CB1 Transmembrane Helix 7
Mol. Pharmacol., June 1, 2007; 71(6): 1512 - 1524.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics